<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02500784</url>
  </required_header>
  <id_info>
    <org_study_id>SAL0004APR</org_study_id>
    <nct_id>NCT02500784</nct_id>
  </id_info>
  <brief_title>Improving Beta-2 Adrenergic Signaling in Alzheimer's Disease</brief_title>
  <official_title>Improving Beta-2 Adrenergic Signaling in Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Palo Alto Veterans Institute for Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alzheimer's Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mylan Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Palo Alto Veterans Institute for Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the effects of long-term therapeutic doses of
      formoterol, on a) cerebrospinal fluid (CSF) tau levels, and Amyloid Beta protein 40/42 levels
      in the CSF, and b) cognitive function in people with mild to moderate Alzheimer' Disease
      (AD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to test the effects of long-term therapeutic doses of
      formoterol, on a) cerebrospinal fluid CSF tau levels, and A-beta amyloid protein 40/42
      levels, and b) cognitive function: NE-ergic neurons undergo significant degeneration in AD.
      This system plays a significant role in cognition. Recent studies have indicated that
      increasing NE levels in the brain would significantly improve microglia migration and
      clearance of A-beta amyloid protein 40/42 levels in mouse models of AD. The investigators
      plan to test whether long- term daily treatment with inhaled formoterol solution would
      improve the structure and function of hippocampal neurons in AD. Study Design: Randomization
      and initiation of experimental treatment: All participants will be given formoterol daily for
      52 weeks. The active regimen will be initiated as (20 micro gram, BID). The dose will be
      decreased if there is evidence of side effects, including cardiac or respiratory alteration
      changes, gastro-intestinal disturbances or neurological issues.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cognition Evaluation</measure>
    <time_frame>1 Month</time_frame>
    <description>Participants will be administered the CANTAB every month for 16 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brain-derived neurotrophic factor (BDNF) Evaluation</measure>
    <time_frame>Baseline and month 16</time_frame>
    <description>Samples of Plasma and Cerebral Spinal Fluid Biomarkers will be taken at baseline and month 16</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Amyloid accumulation</measure>
    <time_frame>Baseline and month 16</time_frame>
    <description>Molecular Imaging will be taken at baseline and month 16</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Alzheimer's Disease</condition>
  <condition>Cognitive Dysfunction</condition>
  <arm_group>
    <arm_group_label>Formoterol A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>12 months, formoterol, 20microgram/2ml, inhaler, BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formoterol B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>12 months, normal sailine, 2ml, inhaler, BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol A</intervention_name>
    <description>20mg/2mL, BID inhaler for 12 months: until progression or unacceptable toxicity develops.</description>
    <arm_group_label>Formoterol A</arm_group_label>
    <other_name>Performist</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol B</intervention_name>
    <description>2mL, BID inhaler for 12 months</description>
    <arm_group_label>Formoterol B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females between the ages of 50-85,

          -  Mild-to-moderate AD (NINCDS/ADRDA criteria for probable AD will be used to establish
             AD diagnosis).

          -  MMSE 16-26.

        Exclusion Criteria:

          -  Non-AD dementia or significant neurological disease such as Parkinson's disease,
             stroke, brain tumor,multiple sclerosis, seizure disorder, focal brain lesion, or head
             injury with loss of consciousness.

          -  Hypothyroidism, congestive heart failure (New York Heart Association Class III or IV),
             significant extrapyramidal symptoms on neurological examination, serum creatinine&gt;1.3
             mg/dl, significant arrhythmias or conduction defect abnormalities on ECG,

          -  Use of another beta2 adrenergic drug within the last 2 months.

          -  Residence in a long-term care facility.

          -  Evidence of any significant clinical disorder or laboratory finding that renders the
             person unsuitable for receiving an investigational new drug.

          -  Known hypersensitivity or prior exposure to formoterol.

          -  Active asthma or family history of asthma.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmad Salehi, M.D.,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford Medical School</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Atoossa Fahimi, M.D.,Psy.M.</last_name>
    <phone>650-493-5000</phone>
    <phone_ext>65996</phone_ext>
    <email>afahimi@stanford.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fatemeh S Mojabi, M.D.</last_name>
    <phone>650-493-5000</phone>
    <phone_ext>65996</phone_ext>
    <email>fsmojabi@stanford.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>VA Palo Alto Health Care System</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2015</study_first_submitted>
  <study_first_submitted_qc>July 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2015</study_first_posted>
  <last_update_submitted>February 9, 2017</last_update_submitted>
  <last_update_submitted_qc>February 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>VA Palo Alto Health Care System</investigator_affiliation>
    <investigator_full_name>J. Wesson Ashford</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Adrenergic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

